The ace-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters

Thrombosis Research

Volumn 83, Issue 2, 1996, Pages 143-152

  Zehetgruber, Manfred ^a   Beckmann, Renate ^b   Gabriel, Harald ^b   Christ, Günter ^b   Binder, Bernd R ^b   Huber, Kurt ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

glucose tolerance test; insulin; lisinopril; plasminogen activator inhibitor 1; tissue plasminogen activator

Indexed keywords

ACETYLSALICYLIC ACID; ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; LISINOPRIL; NITRATE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FIBRINOLYSIS; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN METABOLISM; MALE; PRIORITY JOURNAL; RISK MANAGEMENT;

EID: 0030586194     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(96)00115-6     Document Type: Article

References (37)

1. 1. MODAN, M., HALKIN, H., ALMOG, S., LUSKY, A., ESHKOL, A., SHEFI, M., SHITRIT, A., FUCHS, Z. Hyperinsulinemia. A link between hypertension, obesity and glucose intolerance. J Clin Invest 75, 809-817, 1985.
2. 2. PYORALA, K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2, 154-160, 1979.
3. 3. REAVEN, G.M. Role of insulin resistance in human disease. Diabetes 37, 1595-1607, 1985.
4. 4. HAMSTEN, A., WIMAN, B., DE FAIRE, U., BOMBACK, M. Increased plasma levels of a rapid inhibitor of tisue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313, 1557-1563, 1985.
5. 5. KRUITHOF, E. K. O., GUDINCHET, A., BACHMANN, F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemostas 59, 7-12, 1988.
6. 6. WRIGHT, R. A., FLAPAN, A. D., ALBERTI, K. G. M. N., LUDLAM, C.A., FOX, K. A. A. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 24, 67-73, 1994.
7. 7. JANSSON, J. H., BOMAN, K., NILSON, T. K. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 44, 485-488, 1993.
8. 8. The SOLVD Investigators Effect of enalapril in survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325, 293-302, 1991.
9. 9. The SOLVD Investigators Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327, 685-691, 1992.
10. 10. VAGUE, P., JUHAN-VAGUE, I., AILAUD, F., BADIER, C., VIARD, R., ALESSI, M.C., COLLEN, D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 2, 250-253, 1986.
11. 11. JUHAN-VAGUE, I., VAGUE, P., ALESSI, M.C., BADIER, C., VALADIER, J., AILAUD, M. F. Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabetes Metabol 13, 331-336, 1987.
12. 12. SELJEFLOT, I., ERITSLAND, J., TORJESEN, P., ARNESEN, H. Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease. Scand J Clin Lab Invest 54, 241-246, 1994.
13. 13. MC CORMACK, L., STICKLAND, M. H., GRANT, P. J. Plasminogen activator inhibitor-1 antigen concentration during insulin and oral glucose tolerance tests in obese man. Fibrinolysis 7, 225-228, 1993.
14. 14. VAGUE, P., JUHAN-VAGUE, I., ALESSI, M. C., BADlER, C., VALADIER, J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non diabetic obese subjects. Thromb Haemostas 57, 326-328, 1987.
15. 15. GRANT, P. J., STICKLAND, M. H., BOOTH, N. A., PRENTICE, C. R. M. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor 1 in type 2 diabetic patients. Diab Med 8, 361-365, 1991.
16. 16. GOLAY, A., FELBER, J. P., DUSMET, M., GOMEZ, F., CURCHOD, B., JEQUIER, E. Effect of weight loss on glucose disposal in obese and obese diabetic patients. Int J Obes 9, 181-190, 1985.
17. 17. POLLARE, T., LITHELL, M., BERNE, C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321, 868-873, 1989.
18. 18. PAOLISSO, G., GAMBARDELLA, A., VERZA, M., D'AMORE, A., SGAMBATO, S., VARRICCHIO, M. ACE inhibition improves insulin-sensitivity in aged insulin resistant hypertensive patients. J Hum Hypertens 6, 175-179, 1992.
19. 19. OKSA, A., GAJDOS, M., FEDELESOVA, V., SPUTOVA, V., DZURIK, R. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol 23, 79-86, 1992.
20. 20. KORNINGER, C., SPEISER, W., WOJTA, J., BINDER, B. R. Sandwich ELISA for tPA antigen employing a monoclonal antibody. Thromb Res 41, 527-535, 1986.
21. 21. WOJTA, J., HOLZER, M., HUFNAGL, P., CHRIST, G., HOOVER, R., BINDER, B. R. Hyperthermia stimulates plasminogen activator inhibitor type-1 expression in human umbilical vein endothelial cells in vitro. Am J Patriot 139, 911-919, 1991.
22. 22. MAHEUX, P., JEPPESEN, J., SHEU, W. H., HOLLENBECK, C. B., CLINKINGBEARD, C., GREENFIELD, M. S., CHEN Y., REAVEN, G. M. Additive effects of obesity, hypertension, and Type 2 diabetes on insulin resistance. Hypertension 24, 695-698, 1994.
23. 23. TOHGI, H., TAKAHASHI, H., CHIBA, K., TAMURA, K. Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication. Stroke 24, 801-804, 1993.
24. 24. MOUSA, S.A., FORSYTHE, M.S., BOZARTH, J.M., REILLY, T.M. Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology 83, 367-373, 1993.
25. 25. ASPLUND-CARLSON, A., HAMSTEN, A., WIMAN, B., CARLSON, L. A. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo and hypertriglyceridaemic men. Diabetologia 36, 817-825, 1993.
26. 26. RIDKER, P. M., GABOURY, C. L., CONLIN, P. R., SEELY, E. W., WILLIAMS, G. H., VAUGHAN, D. E. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the reninangiotensin system and fibrinolytic function. Circulation 87, 1969-1973, 1993.
27. 27. FEENER, E. P., NORTHRUP, J. M., AIELLO, L. P, KING, G. L Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 95, 1353-1362, 1995.
28. 28. VAGUE, P., JUHAN-VAGUE, I., AILLAUD, M.F., BADIER, C., VIARD, R., ALESSI, M.C., COLLEN, D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 2, 250-253, 1986.
29. 29. NORDT, T.K., KLASSEN, K.J., SCHNEIDER, D.J., SOBEL, B.E. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Atheroscler Thromb 13, 1822-1828, 1993.
30. 30. LANDIN, K., TENGBORN, L., CHMIELEWSKA, J., SCHENK, H., SMITH, U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemostas 65, 130-133, 1991.
31. 31. GRANT, P. J., KRUITHOF, E. K. O., FELLEY, C. P., FEBER, J. P., BACHMANN, F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 79, 513-516, 1990.
32. 32. VUORINEN MARKKOLA, H., PUHAKAINEN, I., YKI-JÄRVINEN, H. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemostas 67, 117-120, 1992.
33. 33. SELJEFLOT, I. ERITSLAND, J., TORJESEN, P., ARNESEN, H. Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary artery disease. Scand J Clin Invest 54, 241-246, 1994.
34. 34. ANGLETON, P., CHANDLER, W. L., SCHMER, G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 79, 101-106, 1989.
35. 35. KLUFT, C., JIE, A. F. H., RIJKEN, D. C., VERHEIJEN, J. H. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast acting inhibitor PAI-1. Thromb Haemostas 59, 329-332, 1988.
36. 36. LAGER, I., ATTVALL, S., ERIKSSON, BM., VON SCHENK, H., SMITH, U. Studies on the insulin antagonistic effect of catecholamines in normal man. Evidence for the importance of β-receptors. Diabetologia 29, 409-416, 1986.
37. 37. RIZZA, R., CRYER, PE., GERICH, JE. Role of glucagon, catecholamines, and growth hormone in human glucose counteraction. J Clin Invest 64, 62-71, 1979.